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ObjectiveaaTo analyze both differentially expressed genes and the Bcl-xL protein expression after acute and chronic treatment with fluox-
etine in rat C6 glioma cells.
MethodsaaC6 glioma cells were cultured for 24 h or 72 h after treatment with 10 µM fluoxetine, and gene expression patterns were ob-
served using microarray and qRT-PCR. Then, cells were cultured for 6 h, 24 h, 72 h or 96 h after treatment with 10 µM fluoxetine, and the 
expression of Bcl-xL protein was measured using western blot. 
ResultsaaAs determined by microarray, treatment with fluoxetine for 24 h up-regulated 33 genes (including Bcl-xL and NCAM140) 
and down-regulated 7 genes (including cyclin G-associated kinase). Treatment with fluoxetine for 72 h up-regulated 53 genes (including Gsα 
and Bcl-xL) and down-regulated 77 genes (including Gαi2 and annexin V). Based on the qRT-PCR results, there was an increase in Gsα 
mRNA and a decrease in Gαi2 mRNA at 72 h in fluoxetine-treated cells as compared to control, a result that was consistent with microarray. 
We also observed an increase in Bcl-xL mRNA (both at 24 h and at 72 h) in fluoxetine-treated cells as compared to control, demonstrating a 
tendency to increase gradually. Bcl-xL protein expression increased as the duration of fluoxetine treatment increased.
ConclusionaaThese results suggest that chronic treatment with fluoxetine not only initiates the cAMP pathway through inducing Gsα ex-
pression but also induces Bcl-xL expression, thus inhibiting apoptosis.  Psychiatry Investig 2011;8:161-168
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INTRODUCTION
Fluoxetine, one of the selective serotonin reuptake inhibitors, 
shows a strong antidepressive effect and is widely used to aug-
ment the actions of serotonin (5-HT) in the nervous system.
1,2 
However, like other antidepressants, the clinical effects of fluox-
etine do not begin to appear until a few weeks after the patient 
has begun taking the drug.
3
Previous studies have shown that chronic treatment with an-
tidepressants, including fluoxetine and tianeptine, regulates the 
expression of genes related to intracellular signal transduction 
pathways, including pathways involving cyclic adenosine mo-
nophosphate (cAMP) responsive element binding protein 
(CREB), brain-derived neurotropic factor (BDNF), mitogen-ac-
tivated protein kinase and cell survival, indicating that antide-
pressants may keep nerve cells from being damaged and also help 
them regenerate.
4-7 Nibuya et al.
4 demonstrated that chronic 
treatment with antidepressants, especially imipramine and fluox-
etine, increased CREB and BDNF expression mRNA in rat hip-
pocampus, whereas Reagen et al.
6 found that tianeptine in-
creased BDNF protein levels, not in the rat hippocampus (as 
expected), but in the rat amygdala. This result demonstrated 
that the brain regions that are targeted by antidepressants can 
differ. Recently, chronic treatment (8 weeks) of fluoxetine and 
amitriptyline was shown to increase cyclic guanosine monophos-
phate but not cAMP in rat hippocampus, suggesting that sus-
tained antidepressant treatment may alter cyclic mononucleotide 
messenger systems.
7 However, it is still not fully known how the 
expression of genes related to the cellular mechanisms respon-
sible for the therapeutic effect of antidepressants changes dur-
ing treatment.162  Psychiatry Investig 2011;8:161-168
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In a previous study, we identified genes that may be involved 
in the therapeutic response of fluoxetine using microarray tech-
nology, which can simultaneously monitor the expression 
levels of thousands of genes.
8 In our study using rat basophilic 
leukemia (RBL-2H3) cells, fluoxetine mediated the up- and 
down-regulation of several genes, including 14-3-3 eta, which 
was down-regulated at 24 h and 36 h and then up-regulated at 
48 h. Even though our previous research described a new meth-
od for analyzing the expression pattern of several genes that are 
simultaneously regulated by fluoxetine, there were a few limi-
tations (such as the use of cells that did not originate in the brain 
and the lack of a chronic treatment paradigm for fluoxetine).
The rat C6 glioma cells used in the present study are suitable 
for studying the effects of antidepressants in vitro because the 
cells lacking presynaptic input exhibit directly monoamine re-
ceptor downregulation through postsynaptic action of the an-
tidepressants.
9 In addition, C6 glioma cells have N-methyl-D-
aspartate (NMDA) and dopamine D2 receptors as previously 
mentioned.
10,11 Previous studies have observed 5-HT receptor-
mediated effects using C6 glioma cells.
12,13 Therefore, we can ob-
serve a direct postsynaptic effect as well as the biological func-
tions mediated by NMDA, D2 and 5-HT receptors in the cells 
after fluoxetine treatment. In the present study, we analyzed the 
genes that were up- and down-regulated by acute (24 h) and 
chronic (72 h) treatment with fluoxetine in the cells using cDNA 
microarray. We then confirmed the changes in Gsα, Gαi2, and 
Bcl-xL genes, which were seen in the microarray data, using qua-
ntitative RT-PCR (qRT-PCR). In addition, we measured the ex-
pression level of Bcl-xL protein after fluoxetine treatment us-




The rat C6 glioma cells (KCLB No;10107) were purchased 
from KTCC (Seoul, Korea), a rat brain 10K cDNA chip was 
obtained from Gaiagene (Seoul, Korea) and iQ SYBR green su-
permix was purchased from Bio-Rad (Hercules, CA, USA). 
BCL-xL antibody was purchased from Cell Signaling Technol-
ogy (Beverly, MA, USA) and β-actin was obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Fluoxetine was 
provided by Lilly Korea, Ltd. (Seoul, Korea).
Cell culture and fluoxetine treatment  
C6 cells were grown overnight in Dulbecco’s modified ea-
gle medium containing L-glutamate, 4.5 g/L of glucose, 10% fe-
tal bovine serum, 100 units of penicillin, and 100 μg/mL of strep-
tomycin at 37°C in humidified 5% CO2. As a control, the cells 
were fed with fresh media and cultured for 24 h and 72 h. For 
the fluoxetine treatment group, the cells were fed with fresh me-
dia containing 10 µM of fluoxetine and cultured for 24 h and 72 
h, as was done in a previous study.
14
Microarray analysis  
cDNA microarray analysis was performed using a chip con-
taining 2,500 ESTs and 2,500 known genes. The total RNA 
from the control and fluoxetine-treated cells was isolated using 
TRIzol® Reagent (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s instructions. Fluorescent (Cy3, Cy5)-la-
beled cDNA probes were made from 20 μg of total RNA from 
both the control cells and the fluoxetine-treated cells, using an 
amino-allyl cDNA labeling kit (Ambion, Austin, TX, USA). For 
each experiment, at least four replicates were performed, and 
two of these replicates were repeated with the fluorophores 
reversed to eliminate false-positive results. Cy3- and Cy5-la-
beled probes were mixed with water, 8 μg of poly (dA) (Phar-
macia), 4 μg of Escherichia coli tRNA (Sigma-Aldrich, Saint 
Louis, MO, USA), 10 μg of mouse Cot1 DNA (Invitrogen, Carls-
bad, CA, USA) and 60 μL of 2X EasyHyb buffer (U-vision Bio-
tech Inc., Taipei, Taiwan) to a final volume of 120 μL. The result-
ing mixture was incubated at 95°C for 5 min. Probes were then 
applied to the array for hybridization at 52°C for 8 h, using a 
GeneTAG automatic hybridizer (Genomic Solutions, Boston, 
MA, USA). After hybridization, the slides were washed first in 
2×SSC and 0.2% SDS at 52°C for 5 min, then with 0.1×SSC 
and 0.2% SDS at 52°C for 5 min and finally with 0.1×SSC for 
5 min at room temperature. The slides were dried by spinning 
for 3 min. The dried slides were scanned with a ScanArray 
5,000 fluorescence reader, and QuantArray image acquisition 
software (PerkinElmer Life Sciences) was used to quantify the 
signal and background intensity for each target element. The 
ratio of the two corrected signal intensities was calculated and 
used as the differential expression ratio (DE) for each specific 
gene in the two mRNA samples. The raw data of the repeated 
experiments were converted to log ratios. Negative control spots, 
small signal-to-noise ratio spots that were less than 2 and spots 
whose average sensitivity was less than 7.5 were removed, and the 
data were standardized by Lowess smoothing. Four repeated 
experiments were standardized by the significant analysis of mi-
croarray (SAM; t-statistics) method. Genes differentially expressed 
by fluoxetine were linkage-analyzed using Cluster 3.0 (open source 
clustering software) and visualized using JavaTreeview-1.1.3 soft-




Total RNA from fluoxetine-treated and control cells was iso-
lated using TRIzol
Ⓡ Reagent and reverse transcribed to cDNA 
in order to confirm the expression patterns of the genes Gsα, 
Gαi2, and Bcl-xL which were differentially expressed by fluox-MR Choi et al. 
   www.psychiatryinvestigation.org  163
etine treatment on cDNA microarray result. For qRT-PCR, 12.5 
μL of SYBR
Ⓡ Premix Ex TaqTM II (Takara BIO, Shiga, Japan), 
0.5 μL of ROX, 5 pmol of forward primer, 5 pmol of reverse 
primer and 0.5 μL of cDNA were mixed with water to a final 
volume of 25 μL. The mixture was amplified for 40 cycles 
with an ABI 7500 Real-Time PCR System (Applied Biosys-
tems, Inc., Foster City, CA) with an initial melt at 95°C for ten 
min followed by 40 cycles of 95°C for 15 sec and 60°C for one 
min. The cycle number at which a statistically significant increase 
in each gene was first detected (threshold cycle, Ct) was then nor-
malized to the Ct for β-actin, which was used as an internal con-
trol. The relative expression differences between the control and 
fluoxetine-treated cells were calculated using the 2
-ΔΔCT meth-
od.
15 The primers used to amplify the described genes were list-
ed in Table 1. Primers were designed with Genamics Expression 
software (Genamics, Hamilton, New Zealand). 
Western blot analysis  
The fluoxetine-treated cells were cultured in media contain-
ing 10 µM of fluoxetine for 6 h, 24 h, 72 h or 96 h. The cells 
were then washed in phosphate-buffered saline and harvested. 
Total protein was extracted from the cells using Pro-PrepTM 
(iNtRON Biotechnology, Korea) according to the manufactur-
er’s instructions. The protein was quantified using the Bradford 
method (Bio-Rad Protein Assay Kit; Bio-Rad, Hercules, CA, 
USA). The protein was separated on 12% polyacrylamide gel 
Table 1. Primers used in qRT-PCR
Amplicon Forward (5’-3’) Reverse (5’-3’)
Gsα AATGGGTTTAACGGAGAGGG  ATGGCGGCCACAATGGTTT
Gαi2 AAGGACTGTGGCCTCTTCTGA GCCTTGGGAAACTCTGCAT
Bcl-xL ATCCGTAAAGACCTCTATGC AACGCAGCTCAGTAACAGTC 
β-actin ACCGGAGAGCATTCAGTGAT TGCAATCCGACTCACCAATA
AA859005 (Gsѭ )
24 h    72 h 






24 h 72 h
-3 -2 -1 0 1 2 3
Figure 1. Microarray analysis of fluox-
etine-treated C6 glioma cells. Control 
and 10 µM fluoxetine-treated cells were 
cultured for 24 h or 72 h. Then, 169 dif-
ferentially expressed genes in these 
cells were analyzed using cDNA micro-
array and clustered using a hierarchi-
cal dendrogram. In general, genes in the 
72 h group were more up- or down-reg-
ulated than genes in the 24 h group. 
The gray color indicates that signal in-
tensity was not identified. Three genes 
magnified in the hierarchical dendro-
gram were selected for confirmation of 
their mRNA expression using qRT-PCR.164  Psychiatry Investig 2011;8:161-168
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through sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and electrotransferred onto a nitrocellulose membrane 
(Bio-Rad, Hercules, CA, USA). After blocking with 5% non-
fat dry milk in TBST (20 mM Tris-HCl, pH 7.6; 500 mM 
NaCl, 0.1% Tween 20), the membrane was incubated over-
night at 4°C with the polyclonal rabbit anti-Bcl-xL antibody (1 
: 1,000), followed by incubation with HRP-conjugated anti-
mouse IgG (diluted 1 : 1,000) for 60 min. After washing in 
TBST, the reactions were detected using the enhanced chemi-
luminescence detection system (Amersham Biosciences, Sunny-
vale, CA, USA). The concentration of Bcl-xL exposed on X-ray film 
was quantified with QuantityOne software (Bio-Rad, USA). 
Statistical analysis  
Data were expressed as the mean±standard error. A non-
linear-fitting program (OriginLab Corp., Northampton, MA, 
USA) was used. Paired and unpaired Student’s t-tests were used 
as appropriate to evaluate the statistical significance of differ-
ences between the two groups (fluoxetine-treated and control 
groups). Values of p<0.05 were considered to indicate statisti-
cal significance.
RESULTS
Differentially expressed genes in fluoxetine-treated 
C6 cells  
The gene expression profile of control and 10 μM fluox-
etine-treated cells after 24 h and 72 h was analyzed with a 
chip containing 2,500 ESTs and 2,500 known genes. After 
mining biological data using log_2 (a fold change cut-off of 
1.5), a hierarchical dendrogram of 169 genes was completed 
by clustering differentially expressed genes at 24 h and 72 h af-
ter fluoxetine treatment (Figure 1). Of the 2,500 known genes 
in the chip, 7 genes were down-regulated more than 1.4-fold in 
cells treated with fluoxetine for 24 h compared to the control 
cells, and 77 of 2,500 known genes were down-regulated after 
72 h of fluoxetine treatment. Meanwhile, 33 genes were up-reg-
ulated more than 1.4-fold in fluoxetine-treated cells after 24 h 
compared to control cells, and 53 genes were up-regulated more 
than 1.4-fold in fluoxetine-treated cells after 72 h of treatment.
Table 2 shows a summarized list of time-dependently ex-
pressed genes between the control and fluoxetine-treated C6 
cells. Of the down-regulated genes in fluoxetine-treated cells at 
24 h, cyclin G-associated kinase, which assists heat shock cog-
nate 70 in uncoating clathrin-coated vesicles
16,17 decreased in 
expression by two-fold. In the fluoxetine-treated cells at 24 h, 
Bcl-xL and neural cell adhesion molecule 140 (NCAM140) were 
up-regulated. Bcl-xL (one of the Bcl-2 family members) is widely 
expressed in the adult brain, despite the relative lack of physiolog-
ical apoptosis.
18 
Annexin V and Gαi2 were down-regulated in fluoxetine-
treated cells at 72 h, whereas 14-3-3 eta and Gsα were up-regulated. 
Compared to the expression changes at 24 h, more genes showed 
a change in expression at 72 h. 
Fluoxetine-induced changes in Gsα, Gαi2, and 
Bcl-xL expression  
To confirm the result of the microarray analysis, we per-
formed qRT-PCR on RNA isolated from control and fluox-
etine-treated cells. Gsα mRNA expression was 1.03±0.12-fold 
greater at 24 h and 2.63±0.24-fold greater at 72 h in fluoxetine-
treated cells compared to the control cells as observed in our 
previous study (Figure 2A).
15 On the other hand, Gαi2 expres-
sion was 0.86±0.06-fold at 24 h and 0.72±0.05-fold at 72 h 
compared to control as observed in our previous study (Figure 
2B).
15 Gene expression of Gsα and Gαi2 at 24 h was not signifi-
cantly different from control levels. However, at 72 h, gene ex-
pression of Gsα and Gαi2 was significantly different from ex-
pression in the control cells. Chronic treatment of fluoxetine 
induced up-regulation of Gsα and down-regulation of Giα2, 
which was also found in a previous study.
19 Bcl-xL mRNA sig-
nificantly increased by 1.36±0.13-fold at 24 h and by 1.65± 
0.13-fold at 72 h in fluoxetine-treated cells as compared to con-
trol cells (Figure 2C). The expression in all three of these genes 
changed more after chronic treatment than after acute treatment.   
 
Effect of fluoxetine on Bcl-xL protein expression  
After treating C6 cells with 10 μM fluoxetine and culturing 
them for 6 h, 24 h, 72 h or 96 h, we observed the expression pat-
tern of Bcl-xL protein. Expression gradually increased as treat-
ment time progressed (Figure 3A). The increase of Bcl-xL ex-
pression at 6 h and 24 h was not significantly different in flu-
oxetine-treated cells compared to the control cells (Figure 3B). 
However, at 72 h and 96 h, there was a significant increase in 
Bcl-xL expression compared to control. Therefore, fluoxetine 
increased the expression of the Bcl-xL protein over time.
DISCUSSION
Over the past few decades, theories on depression have sug-
gested that atrophy of neurons from stress, apoptosis or depres-
sion may result from an impairment of the intracellular signal-
ing pathway and a failure of neurons to appropriately adapt.
20,21 
Studies on antidepressants and depression have mainly focused 
on the molecular and cellular antidepressant-induced changes 
that lead to neurogenesis and restored synaptic activity.
We analyzed the genes that were up- and down-regulated as 
a result of acute and chronic treatment with fluoxetine in C6 cells 
and detected expression changes in genes that engage in the in-
tracellular signal transduction cascade, including the following: MR Choi et al. 
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24 h 72 h
Calcium-binding
NM_013132 1.32 0.49 Annexin V
AA998239 1.15 0.50 Calcium channel, voltage-dependent, T type, alpha 1G subunit
A900747 0.98 1.87 ATPase, Ca
++ transporting,cardiac muscle, slow twitch 2
AI137085 1.72 0.81 Nucleobindin
Cell death
AA818903 1.01 1.65 Rap7a, Death-associated protein 1
U10579 2.05 N/I Programmed cell death repressor, Bcl-xL
Cell differentiation & proliferation
AA955554 1.11 0.53 Splicing factor, arginine/serine-rich 5
AA859491 1.57 1.71 Growth response protein (CL-6)
AA964063 0.95 1.72 P105 coactivator
AI137246 1.83 N/I Neural cell adhesion molecule 140 (NCAM140)
Cholesterol metabolism and biosynthesis
AI071179 0.47 N/I Cyclin G-associated kinase
AA998429 1.08 0.52 Squalene epoxidase
Cytoskeleton & filament related components
AA964363 0.46 N/I Plectin
X66870 0.90 0.27 Lamin A
AA997401 0.92 0.47 Four and a half LIM domains 2
AA859231 0.97 0.60 Rat striated muscle alpha-tropomyosin mRNA, 3’end
Peptidase family
AA858753 0.35 N/I Hemopexin
AI548754 0.99 0.44 Proteasome (prosome, macropain) subunit, beta type 4
AA964414 1.22 0.54 Proteasome (prosome, macropain) subunit, alpha type 3
Signal transduction pathway
AA956360 0.98 0.49 Adenylyl cyclase inhibitory Gi2 protein (Gαi2)
AA859005 1.05 1.66 GNAS complex locus (GTP-binding protein G (s),  
  alpha subunit; Gsα)
AA926107 0.94 1.70 Regulator of G-protein signaling 3
AA965154 1.22 0.41 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase  
  activation protein, epsilon polypeptide (14-3-3 epsilon)
AA963196 0.87 1.70 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
  activation protein, eta polypeptide (14-3-3 eta)
Thioredoxin
AI556520 1.02 0.52 DnaJ (Hsp40) homolog, subfamily A, member 2
AA899727 0.99 2.11 Protein disulfide isomerase (prolyl 4-hydroxylase,  
  beta polypepteide)
AI136414 1.69 1.01 DnaJ homolog, subfamily b, member 9
Trafficking & exocytosis
AA819835 1.03 0.49 Annexin A1
AA818465 1.06 0.58 Exportin 1
AA901170 0.99 1.83 Prenylated SNARE protein
L26087 1.69 N/I Munc 18-1/nsec 1166  Psychiatry Investig 2011;8:161-168
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Gsα and Gαi2; neurite outgrowth, including NCAM140; and 
cell survival, such as annexin V and Bcl-xL. Depressed pa-
tients exhibit dysfunction of the cAMP signaling pathway, 
namely a decrease in adenylyl cyclases, the enzymes that gen-
erate intracellular cAMP.
22 This dysfunction occurs in the ce-
rebral cortices of patients with depression. Adenylyl cyclase is 
known to bind with the stimulatory G protein (Gs) and subse-
quently increase cAMP and cAMP-dependent protein kinase.
23 
In the present study, we observed that chronic treatment with 
fluoxetine induced expression of Gsα (the stimulatory α-subunit 
of the Gs protein) mRNA more than 2.5-fold compared to un-
treated control cells, a finding that was similar to previous stud-
ies.
10,24 Toki et al.
24 demonstrated that chronic treatment of C6 
glioma cells with fluoxetine induced a 2-fold increase of Gsα in 
the plasma membrane compared to control cells and also pro-
moted the binding of Gsα and adenylyl cyclase. Chen and Ra-
senick
10 reported that chronic treatment with desipramine, one 
of the tricyclic antidepressants, enhanced the binding of Gsα 
and adenylyl cyclase by 1.7-fold compared to control. In the 
present study, Gαi2 (an antagonist of Gsα) mRNA expression 
was seldom different in cells with acute treatment of fluoxetine 
compared to control cells, but chronic treatment decreased its 
expression by 2-fold in the fluoxetine-treated cells. In a study by 
Emamghoreishi et al.,
19 chronic treatment with desipramine in-
duced a 10% decrease of Gαi2 expression in rat cerebral cortex, 





24 h 72 h
Transcription regulation
AA901256 0.93 1.63 Fos-like antigen 1
AA965094 1.04 1.71 ADP-ribosylation factor 4
AA956793 1.83 1.45 Early growth response protein 1































































Figure 2. mRNA expression of Gsα, Gαi2, and Bcl-xL. C6 glioma cells were incubated with 10 μM fluoxetine for 24 h or 72 h and the resulting 
mRNA from these cells was analyzed by qRT-PCR. A: mRNA levels of Gsα were significantly increased in fluoxetine-treated cells after 72 h com-
pared to control cells. B: mRNA levels of Gαi2 were significantly decreased in fluoxetine-treated cells after 72 h compared to control cells. C: mRNA 
levels of Bcl-xL were significantly increased in fluoxetine-treated cells after both 24 h and 72 h compared to control cells. Values are expressed as 







































































Figure 3. The effect of fluoxetine on Bcl-xL protein expression. 
C6 glioma cells were incubated with 10 μM fluoxetine for 6 h, 24 h, 
72 h or 96 h. A: The result of western blotting using anti-Bcl-xL and 
anti-β-actin antibodies after separating proteins via 12% SDS-PAGE. 
B: The relative expression density of Bcl-xL in fluoxetine-treated cells 
compared to the control. The density of Bcl-xL in fluoxetine-treated cells 
and control cells was normalized with β-actin prior to comparison of 
Bcl-xL density between fluoxetine-treated cells and control cells. Re-
sults are shown as the mean±SEM (n=4). *significantly different from 
control (p<0.05). The data were analyzed by two sample t-test. SDS-
PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis.MR Choi et al. 
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in the control group. When considering the previous studies
10,19,24 
along with our work, chronic treatment with antidepressants 
(specifically fluoxetine) can clearly lead to an increase of Gsα 
and a decrease of Gαi2, suggesting that fluoxetine may activate 
the cAMP signaling pathway. This activation induces genes re-
lated to neuronal survival and synaptic remodeling.
NCAM, which has three major isoforms (NCAM180, 140 and 
120), regulates structural and synaptic plasticity in the brain.
25,26 
In particular, NCAM140 promotes neurite outgrowth.
27 A re-
cent report showed that NCAM140 mRNA is decreased in the 
peripheral blood cells of patients with bipolar disorder, indicat-
ing that this change may be associated with the pathophysiolo-
gy of the disease.
28 Interestingly, we found that NCAM140 
mRNA expression was increased after acute fluoxetine treat-
ment. We hypothesize that fluoxetine may promote neurite out-
growth of damaged neural cells in the brains of depressed pa-
tients through up-regulation of NCAM140. 
Annexin V is a Ca2+-dependent protein that combines with 
phospholipids phosphatidylserine (PS) after the translocation 
of PS from the inside to the outside of the plasma membrane. 
Annexin V expression increases in the early stages of cell death.
29 
In the present study, we observed that chronic treatment with 
fluoxetine led to a 2-fold down-regulation of annexin V com-
pared to control cells.
In the present study, Bcl-xL expression (both mRNA and 
protein) in the C6 cells was up-regulated by both acute and 
chronic treatment with fluoxetine, revealing a tendency for the 
expression level of Bcl-xL to rise as the duration of fluoxetine 
treatment grew longer. As already mentioned, neurotrophic fac-
tors (such as CREB and BDNF) are regulated by stress and an-
tidepressants through cell survival pathways that also control 
the Bcl-2 family proteins.
30,31 Of the Bcl-2 family, Bcl-2 and Bcl-
xL are localized to the mitochondrial outer membrane, act as 
antiapoptotic proteins in intracellular apoptotic signal trans-
duction
32 and are up-regulated by treatment with antidepres-
sants.
5,33 Kosten et al.
33 used an animal model of depression 
to show that both repeated stress and the chronic administra-
tion of antidepressants (such as fluoxetine and reboxetine) dif-
ferentially regulated Bcl-xL mRNA expression in the rat hippo-
campus. They reported that reboxetine increased Bcl-xL mRNA 
in the hippocampus but that fluoxetine did not have an effect 
on Bcl-xL. On the other hand, Chiou et al.
5 observed that Bcl-
xL and Bcl-2 mRNA expression was up-regulated by chronic 
treatment with fluoxetine in lipopolysaccharide (LPS)-treated 
neural stem cells (NSCs) derived from the hippocampus; this 
up-regulation repressed LPS-induced apoptosis in NSCs. Based 
on the results of the present study as well as previous studies,
5,33 
we suggest that when fluoxetine regulates the expression of an-
tiapoptotic agents (Bcl-2 and Bcl-xL), the effects are different in 
vivo and in vitro; for example, Bcl-2 is up-regulated by fluox-
etine in vivo, whereas Bcl-xL is mainly up-regulated in vitro. 
Furthermore, the increase that we see in Bcl-xL protein levels (as 
well as in mRNA levels) induced by chronic treatment with fluox-
etine clearly indicates that fluoxetine inhibits apoptosis through 
the Bcl-xL-related antiapoptotic pathway. This result is unlike 
previous studies, which only demonstrated an increase in Bcl-
xL mRNA.
5,33
In conclusion, our data not only confirmed that chronic treat-
ment of fluoxetine induces Gsα and repressed Gαi2 expression 
but also demonstrated that expression of Bcl-xL (both mRNA 
and protein) is increased by chronic treatment with fluoxetine 
in C6 cells. These results suggest that these genes may play a criti-
cal role in delaying the clinical effects of antidepressants. How-
ever, additional studies are necessary to further analyze the other 
genes found in the microarray and their roles in the effects of 
antidepressants.
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